Roth MKM raised the firm’s price target on Monogram Orthopaedics (MGRM) to $5.40 from $4 and keeps a Buy rating on the shares. The company’s announced FDA 510(k) clearance for its mBos TKA System, a robotic-assisted total knee arthroplasty platform with semi-autonomous cutting, is a major milestone de-risking the regulatory pathway, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGRM:
- Monogram Orthopaedics price target raised to $5.40 from $4 at Roth MKM
- Monogram Orthopaedics Gains FDA Clearance for TKA System
- Monogram Orthopaedics announces 510(k) clearance for mBos TKA System
- Monogram Orthopaedics Earnings Call: Balancing Innovation and Regulatory Challenges
- Monogram Technologies Advances in Orthopedic Robotics